TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of TMDX traded down $0.62 during trading hours on Thursday, reaching $87.24. 692,313 shares of the stock traded hands, compared to its average volume of 688,977. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The company’s 50-day moving average price is $83.01 and its two-hundred day moving average price is $72.88.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s revenue for the quarter was up 158.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) EPS. Research analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Institutional Trading of TransMedics Group

Hedge funds have recently bought and sold shares of the stock. Ancora Advisors LLC purchased a new stake in TransMedics Group in the 1st quarter worth $38,000. First Horizon Advisors Inc. lifted its stake in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Belpointe Asset Management LLC lifted its stake in TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of TransMedics Group by 595.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock worth $50,000 after buying an additional 512 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of TransMedics Group in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, Piper Sandler initiated coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.